NYSE:MRK

Merck & Co., Inc. Stock Forecast, Price & News

$79.14

-0.32 (-0.40%)

(As of 01/26/2022 04:00 PM ET)

Add

Compare

Today's Range: $78.73
▼
$80.34
50-Day Range: $72.28
▼
$83.05
52-Week Range: $70.89
▼
$91.40

Volume: 13.04 million shs
Average Volume: 13.49 million shs
Market Capitalization: $199.90 billion

P/E Ratio: 27.96
Dividend Yield: 3.47%
Beta: 0.49

30 days | 90 days | 365 days | Advanced Chart

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter.

About Merck & Co., Inc.

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

3 Great Healthcare Stocks to Buy Now
January 22, 2022 | marketbeat.com

Introducing the 2022 Dogs of the Dow: 10 High-Yield Blue Chips Paying up to 4.9%
January 20, 2022 | marketbeat.com

Our Disability Inclusiveness Earns Top Employer Award
January 26, 2022 | finance.yahoo.com

U.S. FDA declines to approve Merck's cough drug
January 26, 2022 | reuters.com

FDA has questions about Merck's experimental chronic cough drug
January 26, 2022 | bizjournals.com

FDA rejects Merck drug, threatening millions in payments to Afferent investors
January 26, 2022 | bizjournals.com

Merck Announces Second-Quarter 2022 Dividend
January 25, 2022 | finance.yahoo.com

COVID-19 deaths top 2,100 a day amid Omicron wave
January 25, 2022 | finance.yahoo.com

Large Cap Pharma, Biotech Stocks Down on Regulatory Updates
January 25, 2022 | finance.yahoo.com

Merck: FDA Rejects Gefapixant Application, Requests More Data >MRK
January 24, 2022 | marketwatch.com

Citizens & Northern Corp Buys AmerisourceBergen Corp, PPL Corp, Cisco Systems Inc, Sells ...
January 24, 2022 | finance.yahoo.com

U.S. FDA declines to approve Merck's cough treatment
January 24, 2022 | finance.yahoo.com

Merck says FDA wants more information about its experimental cough treatment
January 24, 2022 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NYSE:MRK
Previous Symbol
CUSIP: 58933Y10
CIK: 310158
Web: www.merck.com
Phone: (908) 740-4000
Fax: 908-735-1253
Employees: 74,000
Year Founded: 1891

Sales & Book Value

Annual Sales: $47.99 billion
Price / Sales: 4.17
Cash Flow: $7.17 per share
Price / Cash Flow: 11.03
Book Value: $10.04 per share
Price / Book: 7.88

Profitability

EPS (Most Recent Fiscal Year): $2.83
Net Income: $7.07 billion
Net Margins: 14.64%
Pretax Margin: 20.25%
Return on Equity: 48.21%
Return on Assets: 16.00%

Debt

Debt-to-Equity Ratio: 0.64
Current Ratio: 1.31
Quick Ratio: 1.07

Price-To-Earnings

Trailing P/E Ratio: 27.96
Forward P/E Ratio: 13.60
P/E Growth: 1.66

Miscellaneous

Outstanding Shares: 2,525,944,000
Free Float: 2,517,861,000
Market Cap: $199.90 billion
Optionable: Optionable

Company Calendar

Last Earnings: 10/27/2021
Ex-Dividend for 1/7 Dividend: 12/14/2021
Dividend Payable: 1/07/2022
Today: 1/26/2022
Next Earnings (Confirmed): 2/03/2022
Fiscal Year End: 12/31/2022

Social Links

MarketRank^™

Overall MarketRank^™

3.11 out of 5 stars

Medical Sector

16th out of 1,416 stocks

Pharmaceutical Preparations Industry

3rd out of 684 stocks

3.3 Analyst's Opinion

Consensus Rating
Merck & Co., Inc. has received a consensus rating of Buy. The company's average rating score is 2.63, and is based on 8 buy ratings, 7 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $92.07, Merck & Co., Inc. has a forecasted upside of 16.3% from its current price of $79.14.
Amount of Analyst Coverage
Merck & Co., Inc. has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

4.5 Community Rank

Outperform Votes
Merck & Co., Inc. has received 892 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Merck & Co., Inc. has received 432 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Merck & Co., Inc. has received 67.37% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Merck & Co., Inc. and other stocks. Vote “Outperform” if you believe MRK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.

3.3 Dividend Strength

Dividend Yield
Merck & Co., Inc. pays a meaningful dividend of 3.47%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Merck & Co., Inc. has been increasing its dividend for 12 years.
Dividend Coverage
The dividend payout ratio of Merck & Co., Inc. is 97.53%. Payout ratios above 75% are not desirable because they may not be sustainable.
Dividend Sustainability
Based on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 40.12% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Merck & Co., Inc. insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $78,682,559.00 in company stock.
Percentage Held by Insiders
Only 0.32% of the stock of Merck & Co., Inc. is held by insiders.
Percentage Held by Institutions
71.43% of the stock of Merck & Co., Inc. is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Merck & Co., Inc. are expected to grow by 18.21% in the coming year, from $5.82 to $6.88 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Merck & Co., Inc. is 27.96, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.24.
Price to Earnings Ratio vs. Sector
The P/E ratio of Merck & Co., Inc. is 27.96, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 16.08.
Price to Earnings Growth Ratio
Merck & Co., Inc. has a PEG Ratio of 1.66. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Merck & Co., Inc. has a P/B Ratio of 7.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

Is Merck & Co., Inc. a buy right now?: 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 7 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Merck & Co., Inc. stock.
View analyst ratings for Merck & Co., Inc. or view top-rated stocks.
How has Merck & Co., Inc.'s stock price been impacted by COVID-19?: Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MRK stock has decreased by 0.1% and is now trading at $79.14.
View which stocks have been most impacted by COVID-19.
When is Merck & Co., Inc.'s next earnings date?: Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Merck & Co., Inc..
How can I listen to Merck & Co., Inc.'s earnings call?: Merck & Co., Inc. will be holding an earnings conference call on Thursday, February 3rd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Merck & Co., Inc.'s earnings last quarter?: Merck & Co., Inc. (NYSE:MRK) issued its quarterly earnings results on Wednesday, October, 27th. The company reported $1.75 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.55 by $0.20. The firm earned $13.15 billion during the quarter, compared to the consensus estimate of $12.32 billion. Merck & Co., Inc. had a net margin of 14.64% and a trailing twelve-month return on equity of 48.21%. The business's revenue was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.74 EPS.
View Merck & Co., Inc.'s earnings history.
How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?: Merck & Co., Inc. announced a quarterly dividend on Tuesday, November 30th. Shareholders of record on Wednesday, December 15th will be paid a dividend of $0.69 per share on Friday, January 7th. This represents a $2.76 dividend on an annualized basis and a yield of 3.49%. The ex-dividend date is Tuesday, December 14th. This is a boost from Merck & Co., Inc.'s previous quarterly dividend of $0.65.
View Merck & Co., Inc.'s dividend history.
Is Merck & Co., Inc. a good dividend stock?: Merck & Co., Inc. pays an annual dividend of $2.76 per share and currently has a dividend yield of 3.47%. Merck & Co., Inc. has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Merck & Co., Inc. is 97.53%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 40.12% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.
View Merck & Co., Inc.'s dividend history.
What guidance has Merck & Co., Inc. issued on next quarter's earnings?: Merck & Co., Inc. issued an update on its FY 2021 earnings guidance on Thursday, November, 4th. The company provided earnings per share (EPS) guidance of $5.650-$5.700 for the period, compared to the Thomson Reuters consensus estimate of $5.770. The company issued revenue guidance of $47.40 billion-$47.90 billion, compared to the consensus revenue estimate of $48.16 billion.
What price target have analysts set for MRK?: 16 Wall Street analysts have issued 12-month target prices for Merck & Co., Inc.'s stock. Their forecasts range from $70.00 to $110.00. On average, they anticipate Merck & Co., Inc.'s stock price to reach $92.07 in the next year. This suggests a possible upside of 16.3% from the stock's current price.
View analysts' price targets for Merck & Co., Inc. or view top-rated stocks among Wall Street analysts.
Who are Merck & Co., Inc.'s key executives?: Merck & Co., Inc.'s management team includes the following people:
Robert M. Davis, President, Chief Executive Officer & Director
Caroline A. Litchfield, Chief Financial Officer & Executive Vice President (LinkedIn Profile)
Sandy Tremps, Vice President-R&D IT CIO
Dave Williams, Chief Information & Digital Officer
Franklin K. Clyburn, Executive VP & President-Human Health
What is Kenneth C. Frazier's approval rating as Merck & Co., Inc.'s CEO?: 1,343 employees have rated Merck & Co., Inc. CEO Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among Merck & Co., Inc.'s employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
Who are some of Merck & Co., Inc.'s key competitors?: Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Nektar Therapeutics (NKTR), Supernus Pharmaceuticals (SUPN) and Zogenix (ZGNX).
View all of MRK's competitors.
What other stocks do shareholders of Merck & Co., Inc. own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and Home Depot (HD).
What is Merck & Co., Inc.'s stock symbol?: Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."
Who are Merck & Co., Inc.'s major shareholders?: Merck & Co., Inc.'s stock is owned by many different institutional and retail investors. Top institutional investors include Nordea Investment Management AB (0.48%), Sarasin & Partners LLP (0.16%), Russell Investments Group Ltd. (0.13%), Van ECK Associates Corp (0.12%), New York State Teachers Retirement System (0.12%) and Strs Ohio (0.08%). Company insiders that own Merck & Co., Inc. stock include Caroline Litchfield, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Richard R Deluca, Rita A Karachun, Robert M Davis, Sanat Chattopadhyay and Wendell P Weeks.
View institutional ownership trends for Merck & Co., Inc..
Which institutional investors are selling Merck & Co., Inc. stock?: MRK stock was sold by a variety of institutional investors in the last quarter, including Coho Partners Ltd., M&G Investment Management Ltd., Nordea Investment Management AB, Russell Investments Group Ltd., Strs Ohio, Retirement Systems of Alabama, Moody National Bank Trust Division, and Gradient Investments LLC. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Caroline Litchfield, Frank Clyburn, Kenneth C Frazier, Richard R Deluca, Rita A Karachun, and Sanat Chattopadhyay.
View insider buying and selling activity for Merck & Co., Inc. or view top insider-selling stocks.
Which institutional investors are buying Merck & Co., Inc. stock?: MRK stock was purchased by a variety of institutional investors in the last quarter, including National Bank of Canada FI, Railway Pension Investments Ltd, Polaris Wealth Advisory Group LLC, Atalanta Sosnoff Capital LLC, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH, Sarasin & Partners LLP, Foundation Resource Management Inc., and Aries Wealth Management.
View insider buying and selling activity for Merck & Co., Inc. or or view top insider-buying stocks.
How do I buy shares of Merck & Co., Inc.?: Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Merck & Co., Inc.'s stock price today?: One share of MRK stock can currently be purchased for approximately $79.14.
How much money does Merck & Co., Inc. make?: Merck & Co., Inc. has a market capitalization of $199.90 billion and generates $47.99 billion in revenue each year. The company earns $7.07 billion in net income (profit) each year or $2.83 on an earnings per share basis.
How many employees does Merck & Co., Inc. have?: Merck & Co., Inc. employs 74,000 workers across the globe.
When was Merck & Co., Inc. founded?: Merck & Co., Inc. was founded in 1891.
What is Merck & Co., Inc.'s official website?: The official website for Merck & Co., Inc. is www.merck.com.
Where are Merck & Co., Inc.'s headquarters?: Merck & Co., Inc. is headquartered at 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033.
How can I contact Merck & Co., Inc.?: Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at (908) 740-4000, via email at [email protected], or via fax at 908-735-1253.

This page was last updated on 1/26/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Merck & Co., Inc. Stock Forecast, Price & News

About Merck & Co., Inc.

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Company Calendar

Social Links

MarketRank™

Overall MarketRank™

3.3 Analyst's Opinion

4.5 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

3.3 Dividend Strength

2.5 Company Ownership

1.9 Earnings and Valuation

Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

Is Merck & Co., Inc. a buy right now?

How has Merck & Co., Inc.'s stock price been impacted by COVID-19?

When is Merck & Co., Inc.'s next earnings date?

How can I listen to Merck & Co., Inc.'s earnings call?

How were Merck & Co., Inc.'s earnings last quarter?

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Is Merck & Co., Inc. a good dividend stock?

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

What price target have analysts set for MRK?

Who are Merck & Co., Inc.'s key executives?

What is Kenneth C. Frazier's approval rating as Merck & Co., Inc.'s CEO?

Who are some of Merck & Co., Inc.'s key competitors?

What other stocks do shareholders of Merck & Co., Inc. own?

What is Merck & Co., Inc.'s stock symbol?

Who are Merck & Co., Inc.'s major shareholders?

Which institutional investors are selling Merck & Co., Inc. stock?

Which institutional investors are buying Merck & Co., Inc. stock?

How do I buy shares of Merck & Co., Inc.?

What is Merck & Co., Inc.'s stock price today?

How much money does Merck & Co., Inc. make?

How many employees does Merck & Co., Inc. have?

When was Merck & Co., Inc. founded?

What is Merck & Co., Inc.'s official website?

Where are Merck & Co., Inc.'s headquarters?

How can I contact Merck & Co., Inc.?

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

MarketRank^™

Overall MarketRank^™